Loading...
Towards identifying potent new hits for glioblastoma
Sherer, Chris Prabhu, Saurabh Adams, David Hayes, Joseph Rowther, Farzana Tolaymat, Ibrahim Warr, Tracy Snape, Timothy J.
Sherer, Chris
Prabhu, Saurabh
Adams, David
Hayes, Joseph
Rowther, Farzana
Tolaymat, Ibrahim
Warr, Tracy
Snape, Timothy J.
Editors
Other contributors
Affiliation
Epub Date
Issue Date
2018-10-02
Submitted date
Subjects
Alternative
Abstract
Glioblastoma is a devastating disease of the brain and is the most common malignant primary brain tumour in adults. The prognosis for patients is very poor with median time of survival after diagnosis measured in months, due in part to the tumours being highly aggressive and often resistant to chemotherapies. Alongside the ongoing research to identify key factors involved in tumour progression in glioblastoma, medicinal chemistry approaches must also be used in order to rapidly establish new and better treatments for brain tumour patients. Using a computational similarity search of the ZINC database, alongside traditional analogue design by medicinal chemistry intuition to improve the breadth of chemical space under consideration, six new hit compounds (14, 16, 18, 19, 20 and 22) were identified possessing low micromolar activity against both established cell lines (U87MG and U251MG) and patient-derived cell cultures (IN1472, IN1528 and IN1760). Each of these scaffolds provides a new platform for future development of a new therapy in this area, with particular promise shown against glioblastoma subtypes that are resistant to conventional chemotherapeutic agents.
Citation
Sherer, C. et al. (2018) Towards Identifying Potent New Hits for Glioblastoma, MedChemComm, 9 (11), pp. 1850-1861. DOI: 10.1039/C8MD00436F
Publisher
Journal
Research Unit
PubMed ID
PubMed Central ID
Embedded videos
Additional Links
Type
Journal article
Language
en
Description
This is an accepted manuscript of an article published by Elsevier in MedChemComm on 02/10/2018, available online: https://doi.org/10.1039/C8MD00436F
The accepted version of the publication may differ from the final published version.
Series/Report no.
ISSN
2040-2503
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
Rights
Attribution-NonCommercial-NoDerivs 3.0 United States